Allelic imbalance and mutations of the PTEN gene in ovarian cancer - PubMed (original) (raw)
. 2000 Jan 15;85(2):160-5.
A Okamoto, T Kohno, S Takakura, H Shinozaki, S Isonishi, T Yasuhara, T Yoshimura, Y Ohtake, K Ochiai, J Yokota, T Tanaka
Affiliations
- PMID: 10629071
Allelic imbalance and mutations of the PTEN gene in ovarian cancer
M Saito et al. Int J Cancer. 2000.
Abstract
The PTEN/MMAC1/TEP1 tumor-suppressor gene, which maps to chromosome 10q23.3, is mutated and homozygously deleted in a variety of human tumors, including endometrioid-type ovarian tumors. We examined 33 primary ovarian cancers and 3 ovarian borderline tumors for allelic imbalance (AI) of the 10q23.3 region using 5 polymorphic markers, including an insertion/deletion-type polymorphic marker identified in intron 4 of the PTEN gene. AI at one or more loci was detected in 12 of 31 (39%) informative ovarian cancers and none of 3 ovarian borderline tumors. The commonly deleted region was mapped between the D10S215 and D10S541 loci, including the PTEN locus. Moreover, the incidence of AI at the PTEN locus (38%) was the highest among the 5 loci examined. Therefore, we searched for mutations in the entire coding region of the PTEN gene by PCR-SSCP and sequencing analyses in these tumors and 7 ovarian cancer cell lines. Mutations were detected in 3 of the 33 (9%) ovarian cancers: 2 cases with double mutations and 1 case with a mutation on 1 allele accompanied by deletions on both alleles in the poly T tract preceding the splice acceptor site in intron 7. An intragenic deletion was detected in 1 of the 7 (14%) ovarian cancer cell lines. PTEN mutations were detected not only in the endometrioid type but also in the serous and mucinous types of ovarian cancer. However, PTEN was not mutated in the 12 tumors that showed AI of the PTEN locus. Our results suggest that the PTEN gene plays an important role in the development of a subset but diverse histological types of ovarian tumors. However, it is possible that another tumor-suppressor gene in the close vicinity of the PTEN gene is also inactivated by AI of the 10q23.3 region.
Copyright 2000 Wiley-Liss, Inc.
Similar articles
- Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors.
Obata K, Morland SJ, Watson RH, Hitchcock A, Chenevix-Trench G, Thomas EJ, Campbell IG. Obata K, et al. Cancer Res. 1998 May 15;58(10):2095-7. Cancer Res. 1998. PMID: 9605750 - Exclusion of a major role for the PTEN tumour-suppressor gene in breast carcinomas.
Freihoff D, Kempe A, Beste B, Wappenschmidt B, Kreyer E, Hayashi Y, Meindl A, Krebs D, Wiestler OD, von Deimling A, Schmutzler RK. Freihoff D, et al. Br J Cancer. 1999 Feb;79(5-6):754-8. doi: 10.1038/sj.bjc.6690121. Br J Cancer. 1999. PMID: 10070865 Free PMC article. - Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues.
Suzuki H, Freije D, Nusskern DR, Okami K, Cairns P, Sidransky D, Isaacs WB, Bova GS. Suzuki H, et al. Cancer Res. 1998 Jan 15;58(2):204-9. Cancer Res. 1998. PMID: 9443392 - Common genetic changes between endometriosis and ovarian cancer.
Obata K, Hoshiai H. Obata K, et al. Gynecol Obstet Invest. 2000;50 Suppl 1:39-43. doi: 10.1159/000052877. Gynecol Obstet Invest. 2000. PMID: 11093060 Review. - [An approach to early genetic alterations in precancerous cells].
Sato N, Nishida M, Noguchi M. Sato N, et al. Hum Cell. 2000 Sep;13(3):103-8. Hum Cell. 2000. PMID: 11197771 Review. Japanese.
Cited by
- Allelic loss of 10q23, the PTEN tumour suppressor gene locus, in Barrett's oesophagus-associated adenocarcinoma.
Kulke MH, Odze RD, Thakore KS, Thomas G, Wang H, Loda M, Eng C. Kulke MH, et al. Br J Cancer. 2001 Mar 23;84(6):748-53. doi: 10.1054/bjoc.2000.1660. Br J Cancer. 2001. PMID: 11259087 Free PMC article. - Frequent loss of PTEN expression is linked to elevated phosphorylated Akt levels, but not associated with p27 and cyclin D1 expression, in primary epithelial ovarian carcinomas.
Kurose K, Zhou XP, Araki T, Cannistra SA, Maher ER, Eng C. Kurose K, et al. Am J Pathol. 2001 Jun;158(6):2097-106. doi: 10.1016/S0002-9440(10)64681-0. Am J Pathol. 2001. PMID: 11395387 Free PMC article. - Early detection and treatment of ovarian cancer: shifting from early stage to minimal volume of disease based on a new model of carcinogenesis.
Kurman RJ, Visvanathan K, Roden R, Wu TC, Shih IeM. Kurman RJ, et al. Am J Obstet Gynecol. 2008 Apr;198(4):351-6. doi: 10.1016/j.ajog.2008.01.005. Am J Obstet Gynecol. 2008. PMID: 18395030 Free PMC article. Review. - Loss of PTEN in Fallopian Tube Epithelium Results in Multicellular Tumor Spheroid Formation and Metastasis to the Ovary.
Dean M, Jin V, Bergsten TM, Austin JR, Lantvit DD, Russo A, Burdette JE. Dean M, et al. Cancers (Basel). 2019 Jun 25;11(6):884. doi: 10.3390/cancers11060884. Cancers (Basel). 2019. PMID: 31242614 Free PMC article. - Dual targeting of phosphoinositide 3-kinase and mammalian target of rapamycin using NVP-BEZ235 as a novel therapeutic approach in human ovarian carcinoma.
Santiskulvong C, Konecny GE, Fekete M, Chen KY, Karam A, Mulholland D, Eng C, Wu H, Song M, Dorigo O. Santiskulvong C, et al. Clin Cancer Res. 2011 Apr 15;17(8):2373-84. doi: 10.1158/1078-0432.CCR-10-2289. Epub 2011 Mar 3. Clin Cancer Res. 2011. PMID: 21372221 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical
Research Materials